| 摘要 |
<p num="1"><br/><br/><br/>The invention relates to conjugates of anti-integrin specific antibodies with <br/>cytotoxic compounds, the synthesis, selection, and use of such conjugates for <br/>use in cancer therapy or other diseases mediated by cell proliferation, cell <br/>migration, or inflammation and which pathology involves angiogenesis or <br/>neovascularization of new tissue. In addition the invention relates to <br/>combination therapy of such diseases wherein the treatment comprises use of <br/>said conjugates in combination with one or more other treatment modalities <br/>including but not limited to: chemotherapy, surgery or radiation therapy. The <br/>preferred conjugates contain maytansinoid compounds linked to the antibody by <br/>a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a <br/>taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a <br/>pyrimidine analog.<br/></p> |
